Evidence map›Paper›PMID 35455396›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Design, Synthesis, and Cytotoxicity and Topoisomerase I/IIα Inhibition Activity of Pyrazolo[4,3-

Chhabi Lal Chaudhary, Seungyun Ko, Chaerim Lee, Yerin Kim, Chanhyun Jung, Soonsil Hyun, Youngjoo Kwon, Jong-Soon Kang, Jae-Kyung Jung, Heesoon Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chhabi Lal ChaudharyCollege of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea.ORCID 0000-0001-8890-7181
Seungyun KoCollege of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea.
Chaerim LeeCollege of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea.
Yerin KimCollege of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea.
Chanhyun JungCollege of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea.
Soonsil HyunCollege of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea.
Youngjoo KwonCollege of Pharmacy, Ewha Womans University, Seoul 03760, Korea.ORCID 0000-0001-6256-3042
Jong-Soon KangKorea Research Institute of Bioscience and Biotechnology, Daejeon 28116, Korea.
Jae-Kyung JungCollege of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea.ORCID 0000-0002-0490-9663
Heesoon LeeCollege of Pharmacy and Medicinal Research Center (MRC), Chungbuk National University, Cheongju 28160, Korea.ORCID 0000-0001-5473-3400

Funding

National Research Foundation of Korea 2017R1A5A2015541National Research Foundation of Korea NRF-2019R1F1A1057601
6 · The paper itself

Abstract

With the several targets of cancer treatment, inhibition of DNA topoisomerase activity is one of the well-known focuses in cancer chemotherapy. Here, we describe the design and synthesis of a novel series of pyrazolo[4,3-

Indexed as

anticancer agentscytotoxic effecthuman topoisomerase I and IIα inhibitorsimino Diels–Alder reactionpyrazolo[4,3-f]quinoline derivatives

Identifiers

PMID35455396
PMCPMC9026320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.